This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bottero, F. Articles by Colnaghi, M. I. Search for Related Content PubMed PubMed Citation Articles by Bottero, F. Articles by Colnaghi, M. I.

Gene Transfection and Expression of the Ovarian Carcinoma Marker Folate Binding Protein on NIH/3T3 Cells Increases Cell Growth in Vitro and in Vivo¹

Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, 20133 Milan, Italy

² To whom requests for reprints should be addressed, at Experimental Oncology E, Istituto Nazionale per lo Studio e la Cura dei Tumori, Via Venezian, 1, 20133 Milan, Italy.

The glycoprotein gp38 is overexpressed in 90% of ovarian carcinomas and recognized by monoclonal antibodies MOv18 and MOv19. This molecule is a high affinity folate binding protein (FBP) and a potential marker for ovarian carcinoma. We have developed a model to investigate the biochemical and biological properties of this folate receptor by transfecting NIH/3T3 cells, which do not endogenously express FBP, with a vector containing the complementary DNA for the gp38 cloned from the ovarian carcinoma cell line IGROV1. The FBP expressed shows features identical to those of the protein produced by IGROV1 cell. The FBP is expressed on the cell membrane in a glycosylphosphatidylinositol-linked form, since it is released by treatment with phosphatidylinositol-specific phospholipase C, and is shed into the culture medium of the NIH/3T3 transfectants. Immunoblot analysis with MAbs MOv18 and MOv19 showed that both the glycosylphosphatidylinositol-linked and the soluble FBP migrate at the same apparent molecular weight as the respective IGROV1 proteins. The FBP-transfected NIH/3T3 cells bound folic acid and internalized about 30-fold more folic acid than mock-transfected cells. Growth analysis revealed that FBP-transfected NIH/3T3 cells like IGROV1 maintained their growth rate after 10 days of culture in medium containing physiological or low folate concentration, and tumors arising after transplanting FBP-tNIH/3T3 cells in nude mice were 3-fold heavier than those arising after transplantation of non-FBP-expressing NIH/3T3 cells. These results suggest a correlation between human ovarian carcinoma growth and FBP overexpression.

¹ This work was partially supported by Associazione Italiana per la Ricerca sul Cancro.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received 6/11/93. Accepted 9/28/93.

This article has been cited by other articles:

				R. Yang, E. A. Kolb, J. Qin, A. Chou, R. Sowers, B. Hoang, J. H. Healey, A. G. Huvos, P. A. Meyers, and R. Gorlick The Folate Receptor {alpha} Is Frequently Overexpressed in Osteosarcoma Samples and Plays a Role in the Uptake of the Physiologic Substrate 5-Methyltetrahydrofolate Clin. Cancer Res., May 1, 2007; 13(9): 2557 - 2567. [Abstract] [Full Text] [PDF]

				I. Hayashi, K.-J. Sohn, J. M. Stempak, R. Croxford, and Y.-I. Kim Folate Deficiency Induces Cell-Specific Changes in the Steady-State Transcript Levels of Genes Involved in Folate Metabolism and 1-Carbon Transfer Reactions in Human Colonic Epithelial Cells J. Nutr., March 1, 2007; 137(3): 607 - 613. [Abstract] [Full Text] [PDF]

				K. L. Knutson, C. J. Krco, C. L. Erskine, K. Goodman, L. E. Kelemen, P. J. Wettstein, P. S. Low, L. C. Hartmann, and K. R. Kalli T-Cell Immunity to the Folate Receptor Alpha Is Prevalent in Women With Breast or Ovarian Cancer J. Clin. Oncol., September 10, 2006; 24(26): 4254 - 4261. [Abstract] [Full Text] [PDF]

				M. S. Jhaveri, A. S. Rait, K.-N. Chung, J. B. Trepel, and E. H. Chang Antisense oligonucleotides targeted to the human {alpha} folate receptor inhibit breast cancer cell growth and sensitize the cells to doxorubicin treatment Mol. Cancer Ther., December 1, 2004; 3(12): 1505 - 1512. [Abstract] [Full Text] [PDF]

				C.-O. Evans, P. Reddy, D. J. Brat, E. B. O'Neill, B. Craige, V. L. Stevens, and N. M. Oyesiku Differential Expression of Folate Receptor in Pituitary Adenomas Cancer Res., July 15, 2003; 63(14): 4218 - 4224. [Abstract] [Full Text] [PDF]

				A. Tomassetti, F. Mangiarotti, M. Mazzi, S. Sforzini, S. Miotti, E. Galmozzi, P. C. Elwood, and S. Canevari The Variant Hepatocyte Nuclear Factor 1 Activates the P1 Promoter of the Human {alpha}-Folate Receptor Gene in Ovarian Carcinoma Cancer Res., February 1, 2003; 63(3): 696 - 704. [Abstract] [Full Text] [PDF]

				S Miotti, M Bagnoli, A Tomassetti, M. Colnaghi, and S Canevari Interaction of folate receptor with signaling molecules lyn and G(alpha)(i-3) in detergent-resistant complexes from the ovary carcinoma cell line IGROV1 J. Cell Sci., January 1, 2000; 113(2): 349 - 357. [Abstract] [PDF]

				X.-L. Sun, H. N. Jayaram, K. Gharehbaghi, Q.-J. Li, X. Xiao, and A. C. Antony Modulation of the Cytotoxicity of 3'-Azido-3'-deoxythymidine and Methotrexate after Transduction of Folate Receptor cDNA into Human Cervical Carcinoma: Identification of a Correlation between Folate Receptor Expression and Thymidine Kinase Activity Cancer Res., February 1, 1999; 59(4): 940 - 946. [Abstract] [Full Text] [PDF]

				X.-L. Sun and X. L. Sun Evidence That a Specific Interaction Between an 18-Base cis-Element in the 5'-Untranslated Region of Human Folate Receptor-alpha mRNA and a 46-kDa Cytosolic trans-Factor is Critical for Translation J. Biol. Chem., October 11, 1996; 271(41): 25539 - 25547. [Abstract] [Full Text] [PDF]